Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Base estimates & calculations
1.3 Data collection
1.4 Forecast calculations
1.5 Data validation
1.6 Data sources
1.6.1 Primary
1.6.2 Secondary
1.6.2.1 Paid sources
1.6.2.2 Unpaid sources
Chapter 2 Executive Summary
2.1 Industry 360-degree synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Growing prevalence of diabetes across the world
3.2.1.2 Rising technological advancements in diabetes care devices
3.2.1.3 Increasing investments by public and private organizations for diabetes care
3.2.2 Industry pitfalls & challenges
3.2.2.1 High cost of diabetes care devices
3.2.2.2 Rigorous regulatory framework
3.3 Growth potential analysis
3.4 Technological landscape
3.5 Diabetes prevalence estimates and forecast, by region
3.6 Cost of diabetes management, by region
3.7 Product pipeline analysis
3.7.1 Diabetes care products in pipeline, 2023
3.8 Reimbursement scenario
3.8.1 Coding and reimbursement
3.8.2 Reimbursement policies and public healthcare sector insurance coverage for insulin delivery systems
3.8.2.1 U.S.
3.8.2.2 Europe
3.9 Regulatory landscape
3.9.1 U.S.
3.9.2 Europe
3.10 Technology landscape
3.10.1 Advancements in blood glucose monitoring systems
3.10.2 Advancements in insulin delivery devices
3.11 Porter’s analysis
3.11.1 Supplier power
3.11.2 Buyer power
3.11.3 Threat of new entrants
3.11.4 Threat of substitutes
3.11.5 Industry rivalry
3.12 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company matrix analysis
4.3 Company market share analysis
4.4 Competitive positioning matrix
4.5 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Product, 2018 – 2032 ($ Mn)
5.1 Key trends
5.2 Blood glucose monitoring devices
5.2.1 Self-monitoring blood glucose meters
5.2.2 Continuous glucose monitors
5.2.3 Testing strips
5.2.4 Lancets
5.3 Insulin delivery devices
5.3.1 Insulin pumps
5.3.1.1 Tubed pumps
5.3.1.2 Tubeless pumps
5.3.2 Pens
5.3.2.1 Reusable
5.3.2.2 Disposable
5.3.3 Pen needles
5.3.3.1 Standard
5.3.3.2 Safety
5.3.4 Syringes
5.3.5 Other devices
Chapter 6 Market Estimates and Forecast, By End-Use, 2018 – 2032 ($ Mn)
6.1 Key trends
6.2 Hospital
6.3 Ambulatory surgical centers
6.4 Diagnostic centers
6.5 Homecare
6.6 Other end-users
Chapter 7 Market Estimates and Forecast, By Region, 2018 – 2032 ($ Mn)
7.1 Key trends
7.2 North America
7.2.1 U.S.
7.2.2 Canada
7.3 Europe
7.3.1 Germany
7.3.2 UK
7.3.3 France
7.3.4 Netherlands
7.3.5 Sweden
7.3.6 Belgium
7.3.7 Denmark
7.3.8 Finland
7.3.9 Norway
7.3.10 Lithuania
7.3.11 Latvia
7.3.12 Estonia
7.3.13 Rest of Europe
7.4 Asia Pacific
7.4.1 Japan
7.4.2 China
7.4.3 India
7.4.4 Australia
7.4.5 South Korea
7.4.6 Rest of Asia Pacific
7.5 Latin America
7.5.1 Brazil
7.5.2 Mexico
7.5.3 Argentina
7.5.4 Colombia
7.5.5 Chile
7.5.6 Peru
7.5.7 Rest of Latin America
7.6 Middle East and Africa
7.6.1 South Africa
7.6.2 Saudi Arabia
7.6.3 UAE
7.6.4 Turkey
7.6.5 Egypt
7.6.6 Israel
7.6.7 Kuwait
7.6.8 Qatar
7.6.9 Rest of Middle East and Africa
Chapter 8 Company Profiles
8.1 Abbott Laboratories
8.2 Arkray, Inc.
8.3 Ascensia Diabetes Care Holding AG
8.4 B. Braun Melsungen AG
8.5 Becton Dickinson and Company
8.6 Bionime Corporation
8.7 DarioHealth Corp.
8.8 Dexcom, Inc.
8.9 Dr. Reddy's Laboratories
8.10 Eli Lilly and Company
8.11 F. Hoffmann-La Roche AG
8.12 Insulet Corporation
8.13 LifeScan, Inc.
8.14 Medtronic Plc
8.15 Nova Biomedical, Inc.
8.16 Novo Nordisk A/S
8.17 Pendiq GmBH
8.18 Sanofi
8.19 Sinocare, Inc.
8.20 Tandem Diabetes Care Inc.
8.21 Ypsomed AG
